New pill could soothe severe eczema without creams

NCT ID NCT06996912

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called HSK44459 in 150 adults with moderate-to-severe atopic dermatitis (eczema). Participants take the drug or a placebo twice daily for 12 weeks. The goal is to see if the drug safely reduces skin redness, swelling, and itch better than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HSK44459
What this could lead to
If successful, this could lead to a new oral treatment option for moderate-to-severe atopic dermatitis, helping reduce skin inflammation and itching.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Affiliated Dermatology Hospital of Shandong First Medical University

    Jinan, Shandong, 250022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.